EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> ASIT Biotech added to its financing round. The biotech will use the money to move its grass pollen rhinitis treatment into a second phase 3 trial later this year. Release

> Prokarium raised $10 million (€8 million) to support clinical development of vaccines against chlamydia, Clostridium difficile and enteric fever. The British biotech is also expanding its R&D team ahead of a push into immuno-oncology. Statement 

> Bavarian Nordic and AstraZeneca agreed to trial CV301 with Imfinzi. The phase 1/2 trial will assess Bavarian’s cancer vaccine and AstraZeneca’s PD-L1 inhibitor in patients with metastatic colorectal or pancreatic cancers. Release

> Valneva and Emergent Biosolutions moved their Zika virus vaccine into phase 1. Data from the trial will dictate whether Emergent exercises its option on the vaccine. Statement

> OSE Immunotherapeutics got the green light to resume enrollment in its Tedopi phase 3. The biotech halted enrollment in the trial last year “due to an emerging benefit/risk balance of the experimental treatment.” Release

> The Brexit Health Alliance set out how negotiators can mitigate the effect of the U.K.’s departure from the European Union on medical research. Report (PDF)